QLYS insider trade: CEO exercises options and executes planned sales

Rhea-AI Filing Summary

Qualys (QLYS) CEO & President Sumedh S. Thakar, also a Director, reported insider transactions on 10/14/2025. He exercised a stock option for 6,500 shares at $25.56 and sold 4,543 shares at $126.4389 and 3,957 shares at $127.2669. The sales were made under a Rule 10b5-1 trading plan adopted on February 26, 2025.

Following the transactions, Thakar directly held 203,951 shares of common stock and had 13,000 derivative securities (stock options) beneficially owned. The option exercised was fully vested and immediately exercisable, with an expiration date of 04/28/2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Thakar Sumedh S

(Last) (First) (Middle)

C/O QUALYS, INC.

919 E. HILLSDALE BLVD.

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUALYS, INC. [ QLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/14/2025		M(1)		6,500	A	$25.56	212,451	D
Common Stock	10/14/2025		S(1)		4,543	D	$126.4389(2)	207,908	D
Common Stock	10/14/2025		S(1)		3,957	D	$127.2669(3)	203,951	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$25.56	10/14/2025		M			6,500	(4)	04/28/2026	Common Stock	6,500	$0	13,000	D

Explanation of Responses:

1. The sale transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 26, 2025.

2. The sale price represents the weighted average price of the shares sold ranging from $125.92 to $126.90 per share. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The sale price represents the weighted average price of the shares sold ranging from $126.93 to $127.64 per share. Upon request by the Commission staff, the Issuer or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

4. The option is fully vested and immediately exercisable.

	/s/ Bruce Posey by power of attorney for Sumedh S. Thakar	10/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did QLYS CEO Sumedh Thakar report on 10/14/2025?

He exercised an option for 6,500 shares at $25.56 and sold 4,543 shares at $126.4389 and 3,957 shares at $127.2669.

Was the QLYS insider sale under a Rule 10b5-1 plan?

Yes. The sales were effected under a Rule 10b5-1 trading plan adopted on February 26, 2025.

How many QLYS shares does the insider hold after these trades?

He beneficially owned 203,951 common shares directly after the reported transactions.

What stock options does the QLYS insider hold after the trades?

He beneficially owned 13,000 derivative securities (stock options) after the transactions.

What were the price ranges for the QLYS sales?

Weighted averages reflect ranges of $125.92–$126.90 and $126.93–$127.64; full breakdowns are available upon request.

Were the exercised QLYS options vested and when do they expire?

The option was fully vested and immediately exercisable, with an expiration date of 04/28/2026.